 |
|
|
| |
Safety and Efficacy of TBR-652, a Chemokine Receptor 5 (CCR5) Antagonist, in HIV-1-Infected, Antiretroviral (ARV) Treatment-Experienced, CCR5 Antagonist-Naïve Patients
|
| |
| |
Reported by Jules Levin
17thCROI, San Francisco, February 16-19, 2010
Calvin Cohen, MD*
Research DirectorCommunity Research Initiative of New EnglandHarvard Medical School
*On behalf of TBR-652-2-201 Study Team
from Jules: this CCR5 drug has a potentially unique characteristic in that it also binds CCR2 which appears to have potentially a clinically anti-inflammatory effect. The company will explore this in future studies. In the last slide you can see the binding inhibition of drug to MCP-1 which is a reflection of its anti-inflammatory affect.
|
| |
|
|
|
|
|
